Table 2. Clinical characteristics of patients evaluated for fibroproliferation within cohort (n = 75).
P value reflects two-tailed z-test for proportions and Welch’s two-tailed t-test for unequal variance for continuous variables.
| Characteristics | Patients with CT scans | ||
|---|---|---|---|
| Fibrosis (n = 20) | No Fibrosis (n = 41) | p-value | |
| Age, average (std dev), range, yr | 51 (13), 20–74 | 55 (13), 28–75 | |
| Male Sex, n (%) | 11 (55%) | 29 (71%) | 0.23 |
| Ethnicity (% Hispanic) | 10 (50%) | 26 (63%) | 0.32 |
| Race (% Black) | 2 (10%) | 6 (15%) | 0.62 |
| BMI, average, kg/m2 | 31.6 | 33.7 | 0.37 |
| OSH Transfer, n (%) | 14 (70%) | 23 (56%) | 0.3 |
| ARDS at enrollment, n (%) | 12 (60%) | 18 (44%) | 0.24 |
| NIV/HFNC at enrollment, n (%) | 2 (10%) | 15 (37%) | 0.03 (*) |
| Mechanical ventilation at enrollment, n (%) | 17 (85%) | 24 (59%) | 0.04 (*) |
| ECLS at enrollment, n (%) | 4 (20%) | 3 (7%) | 0.14 |
| Received dexamethasone, n (%) | 18 (90%) | 35 (85%) | 0.62 |
| Received any dose of COVID vaccination, n (%) | 1 (5%) | 3 (7%) | 0.73 |
| Admission P:F, median (IQR) | 50 (45–85) | 65 (50–82.5) | 0.4 |
| APACHE, median (IQR) | 87.5 (60.3–103.5) | 75 (55–90.5) | 0.18 |
| RALE score, max in first 24h, median (IQR) | 24.5 (13.75–33) | 24 (14–32) | 0.64 |
| COVID+ test to proximal sample date, median (IQR), d | 11 (2–17.5) | 5 (1–9.75) | 0.066 |
| COVID+ test to CT scan, median (IQR), d | 40 (23–57.25) | 18 (5–22) | 0.016 (*) |
| ICU enrollment to CT scan, median (IQR), d | 23.5 (17–45.75) | 11 (0–19) | 0.026 (*) |